Health Condition 1: A199- Miliary tuberculosis, unspecified Health Condition 2: A159- Respiratory tuberculosis unspecified Health Condition 3: A179- Tuberculosis of nervous system, unspecified Health Condition 4: A188- Tuberculosis of other specified organs
Conditions
Interventions
Control Intervention1: Oral administration of Ethambutol 15-25 mg/kg/day for 6 months: Ethambutol drug has been known to cause ocular toxicity which may be irreversible. The use of ethambutol in anti-
Sponsors
Department of Ophthalmology
Eligibility
Inclusion criteria
Inclusion criteria: Newly diagnosed patients of Tuberculosis (Clinically or Microbiologically proven/ Sputum smear positive) from the age of 18 years and above – receiving daily regimen of ATT (2HRZE+4HRE regimen)
Exclusion criteria
Exclusion criteria: Category II, III, IV Tuberculosis patients Moderate-to-severe Glaucoma Hereditary Optic Neuropathy Ischemic Optic Neuropathy Traumatic Optic Neuropathy HIV patients on Anti-Retroviral therapy Ocular TB Tubercular meningitis Any systemic medical condition (e.g., cognitive impairment, Parkinson’s disease, Alzheimer’s disease, Multiple sclerosis and any other neurological or musculoskeletal disease) which might preclude the patient from giving reliable results on investigations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual acuity Best corrected visual acuity Visual fields Colour vision VEP OCT RNFL OCT MACULA Contrast sensitivityTimepoint: first visit at the start of TB treatment second visit at 2 months third visit at 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Deterioration in ocular function or structure in terms of colour vision contrast sensitivity visual acuity visual fields VEP oct scansTimepoint: 2 months & 4 months | — |
Countries
India
Contacts
Public ContactDr Suresh Kumar
Government Medical College & Hospital, Sector-32, Chandigarh
Outcome results
None listed